Travere Therapeutics (TVTX) Tops Q4 EPS by 17c

Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of ($0.47), $0.17 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $74.79 million versus the consensus estimate of $71.08 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• Palo Alto Networks (PANW) PT Raised to $400 at TD Cowen